Literature DB >> 31455746

On the origin of a pathogenic HERV-W envelope protein present in multiple sclerosis lesions.

Klemens Ruprecht1, Jens Mayer2.   

Abstract

Entities:  

Year:  2019        PMID： 31455746      PMCID： PMC6778242          DOI： 10.1073/pnas.1911703116

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  10 in total

1.  The envelope protein of a human endogenous retrovirus-W family activates innate immunity through CD14/TLR4 and promotes Th1-like responses.

Authors:  Alexandre Rolland; Evelyne Jouvin-Marche; Christophe Viret; Mathias Faure; Hervé Perron; Patrice N Marche
Journal:  J Immunol       Date:  2006-06-15       Impact factor: 5.422

2.  Survey of human genes of retroviral origin: identification and transcriptome of the genes with coding capacity for complete envelope proteins.

Authors:  Nathalie de Parseval; Vladimir Lazar; Jean-François Casella; Laurence Benit; Thierry Heidmann
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

3.  pHERV-W envelope protein fuels microglial cell-dependent damage of myelinated axons in multiple sclerosis.

Authors:  David Kremer; Joel Gruchot; Vivien Weyers; Lisa Oldemeier; Peter Göttle; Luke Healy; Jeong Ho Jang; Yu Kang T Xu; Christina Volsko; Ranjan Dutta; Bruce D Trapp; Hervé Perron; Hans-Peter Hartung; Patrick Küry
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-18       Impact factor: 11.205

4.  Human endogenous retrovirus type W envelope protein inhibits oligodendroglial precursor cell differentiation.

Authors:  David Kremer; Tanja Schichel; Moritz Förster; Nevena Tzekova; Corinne Bernard; Paul van der Valk; Jack van Horssen; Hans-Peter Hartung; Hervé Perron; Patrick Küry
Journal:  Ann Neurol       Date:  2013-09-16       Impact factor: 10.422

5.  Human endogenous retrovirus W in brain lesions: Rationale for targeted therapy in multiple sclerosis.

Authors:  Jack van Horssen; Susanne van der Pol; Philip Nijland; Sandra Amor; Hervé Perron
Journal:  Mult Scler Relat Disord       Date:  2016-04-22       Impact factor: 4.339

Review 6.  The multiple sclerosis-associated retrovirus and its HERV-W endogenous family: a biological interface between virology, genetics, and immunology in human physiology and disease.

Authors:  Antonina Dolei; Hervé Perron
Journal:  J Neurovirol       Date:  2008-11-26       Impact factor: 2.643

7.  An N-terminally truncated envelope protein encoded by a human endogenous retrovirus W locus on chromosome Xq22.3.

Authors:  Christina Roebke; Silke Wahl; Georg Laufer; Christine Stadelmann; Marlies Sauter; Nikolaus Mueller-Lantzsch; Jens Mayer; Klemens Ruprecht
Journal:  Retrovirology       Date:  2010-08-24       Impact factor: 4.602

8.  Analysis of transcribed human endogenous retrovirus W env loci clarifies the origin of multiple sclerosis-associated retrovirus env sequences.

Authors:  Georg Laufer; Jens Mayer; Benedikt F Mueller; Nikolaus Mueller-Lantzsch; Klemens Ruprecht
Journal:  Retrovirology       Date:  2009-04-15       Impact factor: 4.602

9.  Inflammatory response of endothelial cells to a human endogenous retrovirus associated with multiple sclerosis is mediated by TLR4.

Authors:  Alain Duperray; Delphin Barbe; Gilda Raguenez; Babette B Weksler; Ignacio A Romero; Pierre-Olivier Couraud; Hervé Perron; Patrice N Marche
Journal:  Int Immunol       Date:  2015-05-08       Impact factor: 4.823

10.  Contribution of type W human endogenous retroviruses to the human genome: characterization of HERV-W proviral insertions and processed pseudogenes.

Authors:  Nicole Grandi; Marta Cadeddu; Jonas Blomberg; Enzo Tramontano
Journal:  Retrovirology       Date:  2016-09-09       Impact factor: 4.602
  10 in total
  9 in total

1.  Reply to Ruprecht and Mayer: Unearthing genomic fossils in the pathogenesis of multiple sclerosis.

Authors:  David Kremer; Hervé Perron; Patrick Küry
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-27       Impact factor: 11.205

Review 2.  Silencing and Transcriptional Regulation of Endogenous Retroviruses: An Overview.

Authors:  Franziska K Geis; Stephen P Goff
Journal:  Viruses       Date:  2020-08-13       Impact factor: 5.048

Review 3.  Endogenous Retroviruses in Nervous System Disorders.

Authors:  Victoria Gröger; Alexander Emmer; Martin S Staege; Holger Cynis
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-16

4.  Cumulative Roles for Epstein-Barr Virus, Human Endogenous Retroviruses, and Human Herpes Virus-6 in Driving an Inflammatory Cascade Underlying MS Pathogenesis.

Authors:  Ute-Christiane Meier; Richard Christopher Cipian; Abbas Karimi; Ranjan Ramasamy; Jaap Michiel Middeldorp
Journal:  Front Immunol       Date:  2021-11-01       Impact factor: 7.561

5.  Human Endogenous Retrovirus Type W Envelope from Multiple Sclerosis Demyelinating Lesions Shows Unique Solubility and Antigenic Characteristics.

Authors:  Benjamin Charvet; Justine Pierquin; Joanna Brunel; Rianne Gorter; Christophe Quétard; Branka Horvat; Sandra Amor; Jacques Portoukalian; Hervé Perron
Journal:  Virol Sin       Date:  2021-03-26       Impact factor: 4.327

6.  Human Endogenous Retroviruses (HERVs) and Mammalian Apparent LTRs Retrotransposons (MaLRs) Are Dynamically Modulated in Different Stages of Immunity.

Authors:  Maria Paola Pisano; Nicole Grandi; Enzo Tramontano
Journal:  Biology (Basel)       Date:  2021-05-05

Review 7.  Human Endogenous Retrovirus as Therapeutic Targets in Neurologic Disease.

Authors:  Karen Giménez-Orenga; Elisa Oltra
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-24

Review 8.  Role of Viruses in the Pathogenesis of Multiple Sclerosis.

Authors:  Rachael E Tarlinton; Ekaterina Martynova; Albert A Rizvanov; Svetlana Khaiboullina; Subhash Verma
Journal:  Viruses       Date:  2020-06-13       Impact factor: 5.048

Review 9.  High-Throughput Sequencing is a Crucial Tool to Investigate the Contribution of Human Endogenous Retroviruses (HERVs) to Human Biology and Development.

Authors:  Maria Paola Pisano; Nicole Grandi; Enzo Tramontano
Journal:  Viruses       Date:  2020-06-11       Impact factor: 5.048
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.